Background: Symmetric dimethylarginine (SDMA) is a byproduct of protein methylation. Once released from proteins, SDMA is eliminated by the kidneys; consequently, plasma concentration has been suggested as a sensitive marker of renal function. Furthermore, recent work implicates SDMA in the pathogenesis of cardiovascular disease. To date, reference limits for SDMA plasma concentrations in healthy individuals are lacking. Methods: This study defined reference limits for plasma SDMA concentrations in 840 relatively healthy individuals of the Offspring Cohort from Framingham Heart Study (mean age 56 years, 61% women). Plasma SDMA concentrations were determined by LC-MS/MS using a stable isotope dilution assay. Results: The median SDMA concentration in the reference
Introduction
We have recently reported reference limits for asymmetric dimethylarginine (ADMA) using a reference sample from the Framingham Offspring Cohort (1) . ADMA is an endogenous inhibitor of nitric oxide synthase (NOS), a cardiovascular risk factor, and higher levels are linked to greater risk of mortality and morbidity in humans (2) . Unlike ADMA, symmetric dimethylarginine (SDMA) is only a weak endogenous inhibitor of NOS and its pathophysiological role is unclear (3) . Nevertheless, plasma SDMA is elevated in patients with impaired renal function, higher concentrations predict adverse outcomes in patients with prevalent cardiovascular disease and levels are also inversely associated with insulin resistance (4) (5) (6) (7) (8) . Analytical methods for the measurement of plasma SDMA concentrations are based on fluorescence and mass spectrometric (MS) detection. We have recently reported a liquid chromatography (LC)-tandem MS method for the simultaneous quantification of circulating ADMA and SDMA concentrations using stable isotope dilution (9) . Applying this method, we now formulate reference intervals for plasma SDMA in healthy participants attending the 6th examination cycle of the Framingham Offspring Cohort.
Materials and methods
The design and selection criteria of the original Framingham Heart Study (FHS) have been described elsewhere (www.framinghamheartstudy.org/). The Offspring Cohort represents the children of the original participants and their spouses -the 6th examination cycle being performed from 1995 to 1998 as described previously (1) . All participants provided written informed consent and the study protocol was approved by the Institutional Review Board at the Boston University Medical Center. Of the 3532 participants, we initially excluded participants from the present investigation for the following reasons: 1079 with a serum creatinine level outside the creatinine reference limits (i.e., 64-105 mmol/L for men and 49-90 
Results
The biochemical and clinical characteristics of our reference sample are given in Table 1 . The mean age of the reference sample was 56 years, 61% of participants were women. Compared to men, women had a lower body mass index, blood pressure, fasting glucose, total cholesterol/HDL ratio, total homocysteine, eGFR, serum creatinine (all p-0.001), as well as LDL cholesterol and triglycerides (pF0.01). Plasma ADMA concentrations were similar in men wmean"SD, Also, statistically significant age-and sex-adjusted correlations were observed between plasma SDMA and ADMA, body mass index, serum creatinine, eGFR and total homocysteine (rs0.43, -0.13, 0.12, -0.12 and 0.14, respectively, p-0.001 for all) and diastolic blood pressure (rs-0.10, p-0.01).
The results of the multivariable regression models with SDMA as the dependent variable are shown in Table 2 . All candidate independent variables were included in a stepwise selection procedure (cut-off for model entry p-0.1) and a final model was created. Neither sex, alcohol intake, systolic blood pressure, blood lipids, fasting glucose nor high sensitive CRP met the inclusion criteria. Data for men and women were combined since plasma SDMA concentrations were similar in the two sexes. In the final regression model, serum creatinine, age and total homocysteine were positively associated with SDMA, whereas the body mass index and diastolic blood pressure were inversely related ( Table 2 ). An alternative regression model that included log eGFR (instead of serum creatinine) yielded similar results with total homocysteine being positively associated with SDMA, whereas the body mass index and log eGFR were inversely related. Of note, the explanatory power of both models was comparable (R 2 s0.08 for both). LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate. The log eGFR was calculated using the CKD-EPI formula. Candidate variables that were considered for model entry were age, sex, body mass index, systolic and diastolic blood pressure, total/HDL cholesterol ratio, triglycerides, serum creatinine, fasting glucose, total homocysteine, alcohol consumption and log CRP. Regression coefficients (beta estimates) represent the estimated mean change in SDMA (mmol/L) per 1-unit increase in the corresponding covariate.
Discussion
The structural isomer of ADMA, i.e., SDMA, is regarded to be biochemically inert. It is eliminated by the kidney and enzymes metabolizing SDMA are unknown to date. However, recent work from our and other groups suggests that SDMA may interact with L-arginine transport and metabolism and, moreover, that plasma SDMA is a cardiovascular risk factor independent of its association with other markers of renal (dys)function (5) (6) (7) 12) . Of note, the association of SDMA for a composite cardiovascular end-point (stroke, TIA, myocardial infarction and vascular death) was stronger in the population-based Bruneck study as compared with the association of ADMA with the same composite outcome (5) . In this community-based cohort, plasma ADMA concentration was found to be higher as compared with that of SDMA, a finding consistent with our observations. Our reference limits for plasma SDMA are within the range of values reported in healthy individuals by other investigators (13, 14) , but lower than that reported from the Bruneck study (5) . The relations of plasma SDMA concentrations to sex have been inconsistent in the published literature (5, 14) . In our sample, sex was not a statistically significant correlate of SDMA plasma concentrations in multivariable analyses. Interestingly, pre-menopausal women exhibited lower SDMA plasma concentrations than post-menopausal women in our cohort, possibly related to their lower age. Plasma SDMA was inversely associated with body mass index in multivariable models. In South African people with European ancestors, we have previously reported an inverse association between circulating SDMA and insulin resistance (8) . However, in our reference cohort we did not observe an association between SDMA and fasting glucose.
It has been reported that SDMA activates store-operated calcium channels (SOCs, (15) ). This activation of SOCs by SDMA is accompanied by an increased oxidative burden. Oxidative stress also links SDMA with homocysteine and ADMA (16) . We previously reported a close link between homocysteine and ADMA in the Framingham reference sample; in the present investigation we extend this association to SDMA (1) . Also, SDMA increases with age, which is also evident for ADMA (1) . A close link of SDMA with renal function has been well established in patients with chronic kidney and cardiovascular disease (17) . Data are now provided from our and other cohorts that this notion at least partly is true for healthy individuals.
In summary, we report reference limits for plasma SDMA concentration using a reference sample from the FHS and suggest that circulating levels are influenced by renal function, age, blood pressure and body mass index in apparently healthy subjects. These reference limits may form the basis for identification of elevated SDMA plasma concentrations. Our study population is comprised of predominantly white middle-aged individuals and it is important to examine reference limits in other ethnicities.
